Epidemic response group to invest up to $384 mln in Novavax's COVID-19 vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
Novavax (NVAX) PT Raised to $38 at Ladenburg Thalmann
May 12, 2020 8:19 AM EDTLadenburg Thalmann analyst Michael Higgins raised the price target on Novavax (NASDAQ: NVAX) to $38.00 (from $28.00) while maintaining a Buy rating.
The analyst commented, "Last night, Novavax announced its 1Q20 results, presenting a $0.58 loss per share, better than our estimate of -$0.77... More
Inovio Pharma (INO) Misses Q1 EPS by 4c, Revenues Miss
May 11, 2020 5:26 PM EDTInovio Pharma (NASDAQ: INO) reported Q1 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.33 million versus the consensus estimate of $1.91 million.
INOVIO's President and Chief Executive Officer Dr. J. Joseph Kim said, "INOVIO had a very productive first quarter, laying the foundation for a... More
Novavax (NVAX) Tops Q1 EPS by 20c, Revenues Beat
May 11, 2020 5:04 PM EDTNovavax (NASDAQ: NVAX) reported Q1 EPS of ($0.58), $0.20 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $3.38 million versus the consensus estimate of $1.74 million.
Our accomplishments to-date in 2020, including significant progress in our influenza and COVID19 vaccine programs, are the most... More

